MTOR and breast carcinoma: Furthermore, UA has demonstrated the capacity to potentiate adriamycin’s anti-tumor effects by inhibiting proliferation and migration of breast cancer (MDA-MB-231/DOX and MCF-7/ADR) cells, as well as by inducing mitochondrial dysfunction via the AMPK/mTOR/PGC-1α signaling pathway [1047].